AstraZeneca PLC climbed more than 3 percent in the first hour of London trading, pulling the FTSE 100's health-care cluster higher, after the drugmaker said a registrational lung-cancer study met its primary endpoint with a hazard ratio that beat sell-side models circulated last week.

The Cambridge-based group released topline results from a Phase III trial pairing its PD-L1 inhibitor with a novel antibody-drug conjugate in first-line non-small cell lung cancer patients with high PD-L1 expression. Progression-free survival improved versus chemotherapy alone, and the company said overall survival trends favoured the combination although maturity remains short. Full data will be presented at a European oncology congress in December.

Read-through for London-listed peers

GSK and Hikma Pharmaceuticals rose in sympathy, while mid-cap biotechs with lung assets saw sharper moves on thin volume. Marcus Hale's desk tracks liquidity carefully on days like this: when a mega-cap pharma print hits, passive funds rebalance health-care weightings and small names can gap without fresh information.

Analysts at Barclays raised their probability of approval by eight percentage points but kept their price target unchanged pending safety tables, particularly ocular toxicity signals that have dogged earlier ADC classes. "The commercial case hinges on durability," the note said, "not just a headline hazard ratio."

Macro cross-currents

The rally arrived on a morning when oil-sensitive miners weighed on the wider index after Brent crude held above $116, a level that has pressured transport and consumer names this month. Pharma's defensive bid helped the FTSE 100 avoid a deeper opening dip, though banks and insurers still traded softer on gilt-yield volatility ahead of Rachel Reeves' November budget.

Sterling's firm tone against the dollar also helped dollar-reporting pharmas on translation, though AstraZeneca hedges much of its North American exposure. Investors instead focused on US pricing rhetoric: the Trump administration's latest Medicare negotiation list did not include the lung franchise, easing one near-term fear.

What investors watch next

Regulatory filings in the US and EU could follow in the first half of 2027 if survival curves hold. Until then, consensus models will bake in earlier revenue recognition, which matters for a stock that still trades below its 2024 peak despite pipeline wins in respiratory and rare disease.

For pension funds dominated by FTSE weightings, Monday's move is a reminder that health care—not just oil majors—still sets the tone on days when macro headlines scream about energy shocks. The next catalyst is granular: patient-reported outcomes and subgroup analyses that determine whether NHS England will fast-track access discussions.

Fund managers running low-volatility equity strategies increased pharma weightings in morning rebalance programs, according to two brokers who asked not to be named discussing client flows. They cautioned that Monday's pop could fade if safety tables show higher discontinuation rates than chemo alone.

NHS England has not commented on pricing; cost-effectiveness reviews typically follow licensing by several months. Patient groups welcomed early signals but asked for trial diversity tables before celebrating access timelines.